AFT Pharmaceuticals Limited updated earnings guidance for the fiscal year 2024. For the year, the company now expected operating profit, including the company's share of the license fee (estimated at NZD 6 million), to range between $23 million to $25 million. AFT's earlier guidance for operating profit of $22 million to $24 million, excluded the Hikma license income and was subject to finalisation of the US commercialisation plans, and the related investment costs, for Maxigesic Rapid, a prescription-only tablet form of the pain relief medicine approved for sale in the US last year.